Literature DB >> 2548867

Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin.

Q N Luu1, T B Buxton, D R Nelson, J P Rissing.   

Abstract

LY146032 and vancomycin were compared as therapeutic agents in the treatment of chronic Staphylococcus aureus osteomyelitis in the rat. Quantitative cultures disclosed that one of 16, none of 16 and two of 17 tibiae were sterile from the control LY146032, and vancomycin groups, respectively. From positive cultures, geometric mean staphylococcal CFU per gram of bone were as follows: control, 5.13 +/- 1.58; LY146032, 5.36 +/- 0.43 (p = 0.57); and vancomycin, 4.33 +/- 1.73 (p = 0.078). Mean gross pathology was decreased significantly in both treatment groups. LY146032 was no more effective than vancomycin in reducing bacterial counts.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2548867     DOI： 10.1007/BF01967482

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN： 0934-9723            Impact factor:   3.267


  13 in total

1.  Inhibition of peptidoglycan biosynthesis in gram-positive bacteria by LY146032.

Authors:  N E Allen; J N Hobbs; W E Alborn
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

2.  Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

3.  Effect of abscess milieu on bactericidal activity of LY146032 against staphylococci.

Authors:  R E Bryant; J A Mazza; E M Gardner
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

4.  In vitro activity of a new cyclic lipopeptide antibiotic, LY146032, against gram-positive clinical bacteria.

Authors:  P Huovinen; P Kotilainen
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

5.  In vitro activity of LY146032 against staphylococci, streptococci, and enterococci.

Authors:  R J Fass; V L Helsel
Journal:  Antimicrob Agents Chemother       Date:  1986-11       Impact factor: 5.191

6.  Antistaphylococcal activity of a cyclic peptide, LY146032, and vancomycin.

Authors:  C C Knapp; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

7.  Experimental osteomyelitis. II. Therapeutic trials and measurement of antibiotic levels in bone.

Authors:  C W Norden
Journal:  J Infect Dis       Date:  1971-12       Impact factor: 5.226

8.  In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic.

Authors:  G M Eliopoulos; C Thauvin; B Gerson; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1985-03       Impact factor: 5.191

9.  Comparative in vitro activity of LY146032 (daptomycin), a new lipopeptide antimicrobial.

Authors:  R L Hodinka; K Jack-Wait; N Wannamaker; T P Walden; P H Gilligan
Journal:  Eur J Clin Microbiol       Date:  1987-02       Impact factor: 3.267

10.  Model of experimental chronic osteomyelitis in rats.

Authors:  J P Rissing; T B Buxton; R S Weinstein; R K Shockley
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441
View more
  3 in total

1.  Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.

Authors:  W Poeppl; S Tobudic; T Lingscheid; R Plasenzotti; N Kozakowski; H Lagler; A Georgopoulos; H Burgmann
Journal:  Antimicrob Agents Chemother       Date:  2011-08-22       Impact factor: 5.191

Review 2.  Daptomycin: a cyclic lipopeptide antimicrobial agent.

Authors:  LilyAnn Jeu; Horatio B Fung
Journal:  Clin Ther       Date:  2004-11       Impact factor: 3.393

Review 3.  Daptomycin in bone and joint infections: a review of the literature.

Authors:  Dennis A K Rice; Luke Mendez-Vigo
Journal:  Arch Orthop Trauma Surg       Date:  2008-11-07       Impact factor: 3.067
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.